Login to Your Account



Cancer vaccines: Merck stops two tecemotide trials, OSE sails ahead

By Nuala Moran
Staff Writer

Monday, September 15, 2014
LONDON – After surviving one phase III failure, the plug has finally been pulled on tecemotide when it became clear that the cancer vaccine was going to fail a phase II lung cancer study in Japan.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription